The next 12 to 18 months

[bthomas55ep]

Listened to the Cantor webcast. Lots of things working to come to fruition. The host analyst was very knowledgeable and completed a tour of Danbury before the conference. The culmination of the presentation at 31:34 - "the next 12 to 18 months is going to be amazing for the company and our shareholders and our employees - everyone has suffered a long time" - MC

Good presentation - worth a listen. Pipeline of Clofazimine and Nintedanib will bring the story of a technology / delivery company into full view. The goalpost in the Peds Afrezza trial seem to keep moving back, at least for me, but now it seems full enrollment should be by the end of 2023 and a readout should come by June 2024. Was anybody else thinking we were supposed to get an interim readout by now? Thanks. GLTA

[letitride]

I was thinking there was but apparently its just a confirmation that the current enrollment guideline is sufficent and the final read out in june.

[radgray68]

So, I'm going to ask the questions we are all thinking. Which options do I buy and when?

[letitride]

I bought $5 and $6 calls for Febuary bidding $4. I like Feb because by the 3rd Qtr release we should be showing solid continued growth and the run up going into 4th Qtr end of year conf may get real. Feb has been a good month for us in the past.

[cretin11]

Interesting quote: "the next 12 to 18 months is going to be amazing for the company and our shareholders and our employees - everyone has suffered a long time"

Memory might be off, but didn’t he say a few months ago that 2023 would be “phenomenal” for shareholders? Now pushed back to 2024, I wonder what changed. Also, while shareholders have certainly suffered it’s probably not fair to say “everyone” has. But here’s to “the next 12 to 18 months”!